FDA approves GSK & Spero Therapeutics' Tebipenem HBr? Odds & Analysis

poly-0x1b4b89d1eb8b51 ★ POLYMARKET ★ YES/NO ★ poly-0x1b4b89d1eb8b51 ★ POLYMARKET ★ YES/NO ★ poly-0x1b4b89d1eb8b51 ★ POLYMARKET ★ YES/NO ★ poly-0x1b4b89d1eb8b51 ★ POLYMARKET ★ YES/NO ★ poly-0x1b4b89d1eb8b51 ★ POLYMARKET ★ YES/NO ★ poly-0x1b4b89d1eb8b51 ★ POLYMARKET ★ YES/NO ★

← Back

FDA approves GSK & Spero Therapeutics' Tebipenem HBr?

Market price history

Rolling 7-day window of market YES price with the OU fair-price range overlay.

Not enough history yet for a chart.
New points land on each refresh — check back shortly.

Market price

YES75¢ (75%)

NO25¢ (25%)

Latest refresh · prices in cents

Polymarket • Volume: $2.9K • Updated 2h agoCloses: 2026-06-18 (13d)

Polymarket · Companies

OU's Pick

YES at 75¢ · pays 1.3×

Price gap

Polymarket75¢

→

OU's fair82¢

+7¢ underpriced · pays 1.3×

Confidence

Moderate

Spero Therapeutics completed a Phase 3 trial for Tebipenem HBr in January 2025 and resubmitted the New Drug Application with an expected FDA decision date of June 18 2026.

View on Polymarket↗

Affiliate link — we may earn a commission. Not financial advice. For informational purposes only. Prediction markets involve risk of loss. AI may contain errors.